{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:20:01Z","timestamp":1787023201174,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3395,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p>\n                    Cefditoren pivoxil, an oral third\u2010generation cephalosporin, was approved by the Food and Drug Administration in September 2001. It has been used in Japan for several years. The greatest therapeutic potential of cefditoren appears to be its activity against gram\u2010positive and gram\u2010negative organisms causing respiratory tract infections and skin and skin\u2010structure infections, such as\n                    <jats:italic>Haemophilus influenzae, Streptococcus pneumoniae<\/jats:italic>\n                    , and\n                    <jats:italic>Moraxella catarrhalis<\/jats:italic>\n                    . Cefditoren is also effective against methicillin\u2010susceptible strains of\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    . Nevertheless, cefditoren has no activity against atypical pathogens, including\n                    <jats:italic>Chlamydia pneumoniae, Mycoplasma pneumoniae<\/jats:italic>\n                    , and\n                    <jats:italic>Legionella<\/jats:italic>\n                    sp. Moreover, cefditoren does not inhibit\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    or\n                    <jats:italic>Bacteroides fragilis<\/jats:italic>\n                    . In virtually all studies, cefditoren has compared favorably against other orally administered antibiotics used against the most commonly isolated respiratory tract pathogens. Its side effect profile includes diarrhea, nausea, vomiting, headache, and dyspepsia. Cefditoren is indicated for treatment of mild\u2010to\u2010moderate acute exacerbations of chronic bronchitis, pharyngitis\u2010tonsillitis, and uncomplicated skin and skin\u2010structure infections caused by susceptible strains of organisms in adults and adolescents (\u2265 12 yrs of age). Based on its reported antimicrobial activity, cefditoren has potential for empiric management of most commonly encountered respiratory tract infections. Additional studies will further define its role in clinical practice.\n                  <\/jats:p>","DOI":"10.1592\/phco.22.15.1278.33481","type":"journal-article","created":{"date-parts":[[2004,5,28]],"date-time":"2004-05-28T05:38:59Z","timestamp":1085722739000},"page":"1278-1293","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cefditoren, a New Aminothiazolyl Cephalosporin"],"prefix":"10.1002","volume":"22","author":[{"given":"Ebrahim A.","family":"Balbisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"127","article-title":"An in vitro characterization of cefditoren, a new oral cephalosporin","volume":"20","author":"Felmingham D.","year":"1994","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00044-3"},{"key":"e_1_2_1_4_2","volume-title":"Spectracef (cefditoren) package insert","author":"TAP Pharmaceuticals Inc.","year":"2001"},{"key":"e_1_2_1_5_2","first-page":"274","volume-title":"Principles and practice of infectious diseases","author":"Karchmer A.W.","year":"2000"},{"key":"e_1_2_1_6_2","first-page":"145","article-title":"Phase 1 clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers","volume":"23","author":"Li J.T.","year":"1997","journal-title":"Drugs Exp Clin Res"},{"issue":"8","key":"e_1_2_1_7_2","first-page":"43","article-title":"Pharmacokinetics of a new cephalosporin","volume":"22","author":"Sawchuk R.J.","year":"2001","journal-title":"J Respir Dis"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.8.1691"},{"key":"e_1_2_1_9_2","first-page":"197","volume-title":"Antimicrobial activity and in vitro development for cefditoren (CTDR) against streptococci, H. influenzae (HFLU), and M. catarrhalis (MCAT) isolated in 1998\u20131999 [abstr]","author":"Johnson D.M.","year":"1999"},{"key":"e_1_2_1_10_2","volume-title":"Effect of age and gender on the pharmacokinetics of cefditoren [abstr]","author":"Mulford D.","year":"2000"},{"key":"e_1_2_1_11_2","first-page":"55","volume-title":"Effect of renal impairment on the pharmacokinetics of cefditoren [abstr]","author":"Mulford D.","year":"2000"},{"key":"e_1_2_1_12_2","first-page":"59","volume-title":"Effect of hepatic impairment on the pharmacokinetics of cefditoren [abstr]","author":"Mayer M.","year":"2000"},{"key":"e_1_2_1_13_2","first-page":"67","volume-title":"Effect of an H2 receptor antagonist or an antacid on the pharmacokinetics of cefditoren [abstr]","author":"Mayer M.","year":"2000"},{"key":"e_1_2_1_14_2","first-page":"51","volume-title":"Effect of cefditoren on the pharmacokinetics of ethinyl estradiol [abstr]","author":"Mulford D.","year":"2000"},{"key":"e_1_2_1_15_2","first-page":"945","volume-title":"Effect of probenecid on the pharmacokinetics of cefditoren [abstr]","author":"Mayer M.","year":"2001"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(91)90068-Q"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/8.Supplement_3.S237"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00141-3"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.40.2.481","article-title":"Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U\u2010100592 and U\u2010100766), and other oral and parenteral agents against 203 penicillin\u2010susceptible and \u2010resistant pneumococci","volume":"40","author":"Spangler S.K.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00135-8"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2243"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01691969"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00304-2"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.2.141"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00331-5"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063217"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.279"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00160-7"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.5.1038"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048540"},{"key":"e_1_2_1_31_2","first-page":"95","volume-title":"Cefditoren is safe and effective treatment of streptococcal pharyngitis [abstr]","author":"Gooch W.","year":"2000"},{"key":"e_1_2_1_32_2","first-page":"714","volume-title":"Cefditoren is effective treatment for streptococcal pharyngitis [abstr]","author":"Poling T.","year":"1999"},{"issue":"8","key":"e_1_2_1_33_2","first-page":"60","article-title":"A multicenter comparison of cefditoren pivoxil and penicillin VK","volume":"22","author":"Kaplan E.L.","year":"2001","journal-title":"J Resp Dis"},{"key":"e_1_2_1_34_2","first-page":"1538","volume-title":"Cefditoren vs penicillin for streptococcal pharyngitis in children [abstr]","author":"Block S.L.","year":"2001"},{"issue":"8","key":"e_1_2_1_35_2","first-page":"69","article-title":"A double\u2010blind, randomized study of cefditoren vs cefuroxime for AECB","volume":"22","author":"Henry D.C.","year":"2001","journal-title":"J Resp Dis"},{"issue":"8","key":"e_1_2_1_36_2","first-page":"75","article-title":"Treating acute exacerbations of chronic bronchitis","volume":"22","author":"Ramirez J.A.","year":"2001","journal-title":"J Resp Dis"},{"key":"e_1_2_1_37_2","first-page":"711","volume-title":"Safety and efficacy of cefditoren in acute bacterial exacerbation of chronic bronchitis [abstr]","author":"Bettis R.","year":"1999"},{"key":"e_1_2_1_38_2","first-page":"91","volume-title":"Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis (AECB) [abstr]","author":"Tucker R.","year":"2000"},{"key":"e_1_2_1_39_2","first-page":"99","volume-title":"Cefditoren is safe and effective treatment for uncomplicated skin and skin structure infections [abstr]","author":"Millikan L.","year":"2000"},{"key":"e_1_2_1_40_2","first-page":"105","volume-title":"Cefditoren is safe and effective in the eradication of common pathogens in uncomplicated skin and skin structure infections (USSI) [abstr]","author":"Hebert A.","year":"2000"},{"key":"e_1_2_1_41_2","first-page":"87","volume-title":"Efficacy of cefditoren pivoxil (CDTR) vs amoxicillin\u2010clavulanate (AMX\u2010CLV) in acute maxillary sinusitis (AMS) [abstr]","author":"Chow J.","year":"2000"},{"key":"e_1_2_1_42_2","first-page":"852","volume-title":"Cefditoren is effective treatment for community\u2010acquired pneumonia in adults [abstr]","author":"Roux J.","year":"2001"},{"key":"e_1_2_1_43_2","volume-title":"Drug topics red book","author":"Chi J.C.","year":"2002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.15.1278.33481","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.15.1278.33481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:26:46Z","timestamp":1761049606000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.15.1278.33481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1592\/phco.22.15.1278.33481"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.15.1278.33481","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}